Glucose Viaflo Baxter (Glucose)

Glucose Viaflo Baxter is indicated for several clinical situations where rapid carbohydrate supplementation or fluid replacement is required.

• Management of hypoglycemia in patients unable to take oral glucose.
• Component of parenteral nutrition regimens for patients receiving total parenteral nutrition.
• Fluid and electrolyte replacement in perioperative or trauma care.
• Support during dialysis or continuous renal replacement therapy.
• Provision of caloric intake in critically ill patients when enteral feeding is contraindicated.
• Use as a diluent for compatible intravenous medications requiring a glucose-containing carrier.

Glucose Viaflo Baxter may be associated with a range of adverse reactions, most of which are related to its osmolarity and glucose content.

Common

• Transient hyperglycemia, especially in patients with impaired insulin response.
• Local irritation or phlebitis at the infusion site.
• Electrolyte shifts such as mild hyponatremia or hypokalemia due to dilutional effects.
• Mild nausea or vomiting related to rapid infusion rates.

Serious

• Severe hyperglycemia leading to osmotic diuresis or ketoacidosis in susceptible individuals.
• Hypersensitivity reactions including rash, urticaria, or anaphylaxis.
• Fluid overload resulting in pulmonary edema, particularly in patients with cardiac or renal impairment.
• Hyperosmolar state causing neurologic symptoms such as confusion or seizures.

When administering Glucose Viaflo Baxter, clinicians should observe specific precautions to minimize risks and ensure appropriate therapeutic outcomes.

• Assess baseline blood glucose and adjust infusion rate to avoid excessive hyperglycemia.
• Verify patient’s fluid status and cardiac function to prevent volume overload.
• Use aseptic technique and inspect the solution for particulate matter before infusion.
• Monitor electrolytes, particularly sodium and potassium, during prolonged therapy.
• Consider contraindications in patients with known glucose intolerance, uncontrolled diabetes, or severe renal impairment.
• Adjust dosage in pediatric or geriatric populations based on weight and metabolic needs.

Glucose Viaflo Baxter can interact with other intravenous agents or systemic medications; awareness of these interactions helps maintain safety.

Avoid

• Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring, which may precipitate severe hypoglycemia.
• Simultaneous infusion of hypertonic saline solutions that could exacerbate hyperosmolar states.
• Mixing with calcium‑containing solutions may cause precipitation and should be avoided.

Use with caution

• Concurrent use of diuretics that may alter electrolyte balance, requiring closer monitoring.
• Administration alongside potassium‑containing solutions, as glucose infusion can shift potassium intracellularly.
• Use with catecholamine vasopressors, since rapid glucose changes may affect hemodynamic responses.
• When combined with parenteral lipid emulsions, monitor triglyceride levels to prevent hypertriglyceridemia.